MEN1 and pancreatic insulinoma: In conclusion, GDC-0449 was shown to effectively suppress both proliferation of MEN1 tumor beta cells in vivo and reduce insulin secretion by insulinomas, revealing itself to be a promising therapy against MEN1 insulin-secreting pNETs.